Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis

References

• Rachakonda T , Schupp C , Armstrong A. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512-6. doi:10.1016/j.jaad.2013.11.013. PMID:24388724
   PubMed Web of Science ®Google Scholar
• Takeshita J , Grewal S , Langan SM , Mehta NN , Ogdie A , Van Voorhees AS , Gelfand JM . Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76(3):377-90. doi:10.1016/j.jaad.2016.07.064. PMID:28212759
   PubMed Web of Science ®Google Scholar
• Rapp SR , Exum ML , Reboussin DM , Feldman SR , Fleischer A , Clark A . The physical, psychological and social impact of psoriasis. J Health Psychol. 1997;2(4):525-37. doi:10.1177/135910539700200409. PMID:22013093
   PubMedGoogle Scholar
• Rapp SR , Feldman SR , Exum ML , Fleischer AB , Reboussin DM . Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401-7. doi:10.1016/S0190-9622(99)70112-X. PMID:10459113
   PubMed Web of Science ®Google Scholar
• Pearce DJ , Singh S , Balkrishnan R , Kulkarni A , Fleischer AB , Feldman SR . The negative impact of psoriasis on the workplace. J Dermatolog Treat. 2006;17(1):24-8. doi:10.1080/09546630500482886. PMID:16467020
   PubMed Web of Science ®Google Scholar
• Tonel G , Conrad C . Interplay between keratinocytes and immune cells –recent insights into psoriasis pathogenesis. Int J Biochem Cell Biol. 2009;41(5):963-8. doi:10.1016/j.biocel.2008.10.022. PMID:19027868
   PubMed Web of Science ®Google Scholar
• Kim J , Krueger JG . The immunopathogenesis of psoriasis. Dermatol Clin. 2015;33(1):13-23. doi:10.1016/j.det.2014.09.002. PMID:25412780
   PubMed Web of Science ®Google Scholar
• Lowes MA , Kikuchi T , Fuentes-Duculan J , Cardinale I , Zaba LC , Haider AS , Bowman EP , Krueger JG . Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Investig Dermatol. 2008;128:1207-11. doi:10.1038/sj.jid.5701213. PMID:18200064
   PubMed Web of Science ®Google Scholar
• Menter A , Gottlieb A , Feldman SR , Van Voorhees AS , Leonardi CL , Gordon KB , Lebwohl M , Koo JY , Elmets CA , Korman NJ , et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-50. doi:10.1016/j.jaad.2008.02.039. PMID:18423260
   PubMed Web of Science ®Google Scholar
• Chan JR , Blumenschein W , Murphy E , Diveu C , Wiekowski M , Abbondanzo S , Lucian L , Geissler R , Brodie S , Kimball AB , et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203(12):2577-87. doi:10.1084/jem.20060244. PMID:17074928
   PubMed Web of Science ®Google Scholar
• Hong K , Chu A , Ludviksson BR , Berg EL , Ehrhardt RO . IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. I Immuno. 1999;162(12):7480-91. PMID:10358203
   PubMed Web of Science ®Google Scholar
• Presky DH , Yang H , Minetti LJ , Chua AO , Nabavi N , Wu CY , Gately MK , Gubler U . A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Nat Acad Sci. 1996;93(24):14002-7. doi:10.1073/pnas.93.24.14002. PMID:8943050
   PubMed Web of Science ®Google Scholar
• Parham C , Chirica M , Timans J , Vaisberg E , Travis M , Cheung J , Pflanz S , Zhang R , Singh KP , Vega F , et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168(11):5699-708. doi:10.4049/jimmunol.168.11.5699. PMID:12023369
   PubMed Web of Science ®Google Scholar
• Wilson NJ , Boniface K , Chan JR , McKenzie BS , Blumenschein WM , Mattson JD , Basham B , Smith K , Chen T , Morel F , et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nature Immunol. 2007;8(9):950-7. doi:10.1038/ni1497. PMID:17676044
   PubMed Web of Science ®Google Scholar
• Lee E , Trepicchio WL , Oestreicher JL , Pittman D , Wang F , Chamian F , Dhodapkar M , Krueger JG . Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125-30. doi:10.1084/jem.20030451. PMID:14707118
   PubMed Web of Science ®Google Scholar
• Ustekinumab [package insert] . Horsham (PA): Janssen Pharmaceuticals; 2016
   Google Scholar
• Gottlieb AB , Cooper KD , McCormick TS , Toichi E , Everitt DE , Frederick B , Zhu Y , Pendley CE , Graham MA , Mascelli MA . A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opinion. 2007;23(5):1081-92. doi:10.1185/030079907X182112. PMID:17519075
   PubMed Web of Science ®Google Scholar
• Kauffman CL , Aria N , Toichi E , McCormick TS , Cooper KD , Gottlieb AB , Everitt DE , Frederick B , Zhu Y , Graham MA , et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol. 2004;123(6):1037-44. doi:10.1111/j.0022-202X.2004.23448.x. PMID:15610511
   PubMed Web of Science ®Google Scholar
• Krueger GG , Langley RG , Leonardi C , Yeilding N , Guzzo C , Wang Y , Dooley LT , Lebwohl M , CNTO 1275 Psoriasis Study Group . A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. New Eng J Med. 2007;356(6):580-92. doi:10.1056/NEJMoa062382. PMID:17287478
   PubMed Web of Science ®Google Scholar
• Leonardi CL , Kimball AB , Papp KA , Yeilding N , Guzzo C , Wang Y , Li S , Dooley LT , Gordon KB; PHOENIX 1 study investigators . Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665-74. doi:10.1016/S0140-6736(08)60725-4. PMID:18486739
   PubMed Web of Science ®Google Scholar
• Kimball AB , Gordon KB , Fakharzadeh S , Yeilding N , Szapary PO , Schenkel B , Guzzo C , Li S , Papp KA . Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: Results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012;166(4):861-72. doi:10.1111/j.1365-2133.2012.10901.x. PMID:22356258
   PubMed Web of Science ®Google Scholar
• Kimball AB , Papp KA , Wasfi Y , Chan D , Bissonnette R , Sofen H , Yeilding N , Li S , Szapary P , Gordon KB , et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013;27(12):1535-45. doi:10.1111/jdv.12046. PMID:23279003
   PubMed Web of Science ®Google Scholar
• Papp KA , Langley RG , Lebwohl M , Krueger GG , Szapary P , Yeilding N , Guzzo C , Hsu MC , Wang Y , Li S , et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675-84. doi:10.1016/S0140-6736(08)60726-6. PMID:18486740
   PubMed Web of Science ®Google Scholar
• Tsai TF , Ho JC , Song M , Szapary P , Guzzo C , Shen YK , Li S , Kim KJ , Kim TY , Choi JH , et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011;63(3):154-63. doi:10.1016/j.jdermsci.2011.05.005. PMID:21741220
   PubMed Web of Science ®Google Scholar
• Zhu X , Zheng M , Song M , Shen YK , Chan D , Szapary PO , Wang B , LOTUS Investigators . Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: Results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol. 2013;12(2):166-74. PMID:23377389
   PubMed Web of Science ®Google Scholar
• Paul C , Puig L , Kragballe K , Luger T , Lambert J , Chimenti S , Girolomoni G , Nicolas JF , Rizova E , Lavie F , et al. Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: A randomized clinical trial (TRANSIT). Br J Dermatol. 2014;170(2):425-34. doi:10.1111/bjd.12646. PMID:24116959
   PubMed Web of Science ®Google Scholar
• Reich K , Puig L , Paul C , Kragballe K , Luger T , Lambert J , Chimenti S , Girolomoni G , Nicolas JF , Rizova E , et al. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: The TRANSIT randomized trial in moderate-to-severe plaque psoriasis. Br J Dermatol. 2014;170(2):435-44. doi:10.1111/bjd.12643. PMID:24116868
   PubMed Web of Science ®Google Scholar
• Griffiths CE , Strober BE , van de Kerkhof P , Ho V , Fidelus-Gort R , Yeilding N , Guzzo C , Xia Y , Zhou B , Li S , Dooley LT , et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010 Jan 14;362(2):118-28. 27. doi:10.1056/NEJMoa0810652. PMID:20071701
   PubMed Web of Science ®Google Scholar
• Landells I , Marano C , Hsu MC , Li S , Zhu Y , Eichenfield LF , Hoeger PH , Menter A , Paller AS , Taieb A , et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594-603. doi:10.1016/j.jaad.2015.07.002. PMID:26259989
   PubMed Web of Science ®Google Scholar
• Lebwohl M , Leonardi C , Griffiths CE , Prinz JC , Szapary PO , Yeilding N , Guzzo C , Li S , Hsu MC , Strober B . Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol. 2012;66(5):731-41. doi:10.1016/j.jaad.2011.06.011. PMID:21930328
   PubMed Web of Science ®Google Scholar
• Gordon KB , Papp KA , Langley RG , Ho V , Kimball AB , Guzzo C , Yeilding N , Szapary PO , Fakharzadeh S , Li S , et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012;66(5):742-51. doi:10.1016/j.jaad.2011.06.041. PMID:21978572
   PubMed Web of Science ®Google Scholar
• Strober BE , Bissonnette R , Fiorentino D , Kimball AB , Naldi L , Shear NH , Goyal K , Fakharzadeh S , Calabro S , Langholff W , et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol. 2016 May; 74(5):851-61.e4. doi:10.1016/j.jaad.2015.12.017. PMID:26853180
   PubMed Web of Science ®Google Scholar
• Papp K , Gottlieb AB , Naldi L , Pariser D , Ho V , Goyal K , Fakharzadeh S , Chevrier M , Calabro S , Langholff W , et al. Safety Surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706-14. doi:10.4049/jimmunol.1201505. PMID:26151787
   PubMed Web of Science ®Google Scholar
• Yamauchi PS , Bagel J . Next-generation biologics in the management of plaque psoriasis: A literature review of IL-17 inhibition. J Drugs Dermatol. 2015;14(3):244-53. PMID:25738846
   PubMed Web of Science ®Google Scholar
• Johnston A , Fritz Y , Dawes SM , Diaconu D , Al-Attar PM , Guzman AM , Chen CS , Fu W , Gudjonsson JE , McCormick TS , et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013;190:2252-62. doi:10.4049/jimmunol.1201505. PMID:23359500
   PubMed Web of Science ®Google Scholar
• Secukinumab [package insert] . East Hanover (NJ): Novartis Pharmaceuticals; 2016
   Google Scholar
• Hueber W , Patel DD , Dryja T , Wright AM , Koroleva I , Bruin G , Antoni C , Draelos Z , Gold MH , Psoriasis Study Group, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72. doi:10.1126/scitranslmed.3001107. PMID:20926833
   PubMed Web of Science ®Google Scholar
• Papp KA , Langley RG , Sigurgeirsson B , Abe M , Baker DR , Konno P , Haemmerle S , Thurston HJ , Papavassilis C , Richards HB . Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412-21. doi:10.1111/bjd.12110. PMID:23106107
   PubMed Web of Science ®Google Scholar
• Rich P , Sigurgeirsson B , Thaci D , Ortonne JP , Paul C , Schopf RE , Morita A , Roseau K , Harfst E , Guettner A , et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168(2):402-11. doi:10.1111/bjd.12070. PMID:23362969
   PubMed Web of Science ®Google Scholar
• Langley RG , Elewski BE , Lebwohl M , Reich K , Griffiths CE , Papp K , Puig L , Nakagawa H , Spelman L , Sigurgeirsson B , et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. New Engl J Med. 2014;371(4):326-38. doi:10.1056/NEJMoa1314258. PMID:25007392
   PubMed Web of Science ®Google Scholar
• Paul C , Lacour JP , Tedremets L , Kreutzer K , Jazayeri S , Adams S , Guindon C , You R , Papavassilis C , JUNCTURE study group . Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: A randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082-1090. doi:10.1111/jdv.12751. PMID:25243910
   PubMed Web of Science ®Google Scholar
• Blauvelt A , Prinz JC , Gottlieb AB , Kingo K , Sofen H , Ruer-Mulard M , Singh V , Pathan R , Papavassilis C , Cooper S , et al. Secukinumab administration by pre-filled syringe: Efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484-93. doi:10.1111/bjd.13348. PMID:25132411
   PubMed Web of Science ®Google Scholar
• Mrowietz U , Leonardi CL , Girolomoni G , Toth D , Morita A , Balki SA , Szepietowski JC , Regnault P , Thurston H , Papavassilis C , et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1):27-36.e21. doi:10.1016/j.jaad.2015.04.011. PMID:25982539
   PubMed Web of Science ®Google Scholar
• Thaci D , Humeniuk J , Frambach Y , Bissonnette R , Goodman JJ , Shevade S , Gong Y , Papavassilis C , STATURE study group . Secukinumab in psoriasis: Randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015;173(3):777-87. doi:10.1111/bjd.13814. PMID:25823958
   PubMed Web of Science ®Google Scholar
• Abrouk M, Gandy J, Nakamura M, Lee K, Brodsky M, Singh R, Zhu H, Farahnik B, Bhutani T, Koo J . Secukinumab in the treatment of psoriasis and psoriatic arthritis: A review of the literature. Skin Therapy Lett. 2017;22(4):1-6.
   Google Scholar
• van de Kerkhof PC , Griffiths CE , Reich K , Leonardi CL , Blauvelt A , Tsai TF , Gong Y , Huang J , Papavassilis C , Fox T . Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83-98.e84. doi:10.1016/j.jaad.2016.03.024. PMID:27180926
   PubMed Web of Science ®Google Scholar
• López-Ferrer A, Vilarrasa E, Puig L . Secukinumab (AIN457) for the treatment of psoriasis. Expert Rev Clin Immunol. 2015;11(11):1177-88. doi:10.1586/1744666X.2015.1095092.
   PubMed Web of Science ®Google Scholar
• Hueber W , Sands BE , Lewitzky S , Vandemeulebroecke M , Reinisch W , Higgins PD , Wehkamp J , Feagan BG , Yao MD , Karczewski M , et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693-700. doi:10.1136/gutjnl-2011-301668. PMID:22595313
   PubMed Web of Science ®Google Scholar
• Karle A , Spindeldreher S , Kolbinger F . Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. mAbs. 2016;8(3):536-50. doi:10.1080/19420862.2015.1136761. PMID:26817498
   PubMed Web of Science ®Google Scholar
• Taltz [package insert] . Indianapolis (IN): Eli Lilly and Company; 2016
   Google Scholar
• Krueger JG , Fretzin S , Suárez-fariñas M , Haslett PA , Phipps KM , Cameron GS , McColm J , Katcherian A , Cueto I , White T , et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1):145-54.e9. doi:10.1016/j.jaci.2012.04.024. PMID:22677045
   PubMed Web of Science ®Google Scholar
• Leonardi C , Matheson R , Zachariae C , Cameron G , Li L , Edson-Heredia E , Braun D , Banerjee S . Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190-9. doi:10.1056/NEJMoa1109997. PMID:22455413
   PubMed Web of Science ®Google Scholar
• Gordon KB , Leonardi CL , Lebwohl M , Blauvelt A , Cameron GS , Braun D , Erickson J , Heffernan M . A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;71(6):1176-82. doi:10.1016/j.jaad.2014.07.048. PMID:25242558
   PubMed Web of Science ®Google Scholar
• Gordon KB , Blauvelt A , Papp KA , Langley RG , Luger T , Ohtsuki M , Reich K , Amato D , Ball SG , Braun DK , et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345-56. doi:10.1056/NEJMoa1512711. PMID:27299809
   PubMed Web of Science ®Google Scholar
• Griffiths CE , Reich K , Lebwohl M , van de Kerkhof P , Paul C , Menter A , Cameron GS , Erickson J , Zhang L , Secrest RJ , et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials. Lancet. 2015;386(9993):541-51. doi:10.1016/S0140-6736(15)60125-8. PMID:26072109
   PubMed Web of Science ®Google Scholar
• Syed YY . Ixekizumab: A review in moderate to severe plaque psoriasis. Am J Clin Dermatol. 2017;18(1):147-158. doi:10.1007/s40257-017-0254-4. PMID:28138946
   PubMed Web of Science ®Google Scholar
• Strober B , Leonardi C , Papp KA , Mrowietz U , Ohtsuki M , Bissonnette R , Ferris LK , Paul C , Lebwohl M , Braun DK , et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76(3):432-440.e17. doi:10.1016/j.jaad.2016.09.026. PMID:27889292
   PubMed Web of Science ®Google Scholar
• Kimball AB , Schenfeld J , Accortt NA , Anthony MS , Rothman KJ , Pariser D . Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09. Br J Dermatol. 2014;170(2):366-73. doi:10.1111/bjd.12744. PMID:24251402
   PubMed Web of Science ®Google Scholar
• Reich K , Leonardi C , Langley RG , Warren RB , Bachelez H , Romiti R , Ohtsuki M , Xu W , Acharya N , Solotkin K , et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76(3):441-448.e2. doi:10.1016/j.jaad.2016.10.027. PMID:28027825
   PubMed Web of Science ®Google Scholar
• Blauvelt A , Cameron G , Gordon K , et al. Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis [abstract no. 3232]. J Am Acad Dermatol. 2016;74(5 Suppl 1):AB258
   Google Scholar
• SiliqTM [prescribing information] . Bridgewater (NJ): Valeant Pharmaceuticals North America LLC; 2017
   Google Scholar
• Papp KA , Reid C , Foley P , Sinclair R , Salinger DH , Williams G , Dong H , Krueger JG , Russell CB , Martin DA . Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: Results from a phase i, randomized, placebo-controlled trial. J Invest Dermatol. 2012;132(10):2466-9. doi:10.1038/jid.2012.163. PMID:22622425
   PubMed Web of Science ®Google Scholar
• Osamu N , Hirotaka N , Koji S , Kenji T . Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: A randomized, dose-escalation, placebo controlled study. J Dermatol Sci. 2014;75(3):201-4. doi:10.1016/j.jdermsci.2014.05.007. PMID:24957501
   PubMed Web of Science ®Google Scholar
• Papp KA , Leonardi C , Menter A , Ortonne JP , Krueger JG , Kricorian G , Aras G , Li J , Russell CB , Thompson EH , et al. Brodalumab, an anti interleukin-17–receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181-9. doi:10.1056/NEJMoa1109017. PMID:22455412
   PubMed Web of Science ®Google Scholar
• Papp KA , Reid C , Foley P , Sinclair R , Salinger DH , Williams G , Dong H , Krueger JG , Russell CB , Martin DA . Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: Results from a phase i, randomized, placebo-controlled trial. J Invest Dermatol. 2012;132(10):2466-9. doi:10.1038/jid.2012.163. PMID:22622425
   PubMed Web of Science ®Google Scholar
• Papp K , Leonardi C , Menter A , Thompson EH , Milmont CE , Kricorian G , Nirula A , Klekotka P . Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014;71(6):1183-90. doi:10.1016/j.jaad.2014.08.039. PMID:25313095
   PubMed Web of Science ®Google Scholar
• Nakagawa H , Niirob H , Ootaki K , Japanese brodalumab study group . Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81(1):44-52. doi:10.1016/j.jdermsci.2015.10.009. PMID:26547109
   PubMed Web of Science ®Google Scholar
• Papp K , Menter A , Strober B , Kricorian G , Thompson EH , Milmont CE , Nirula A , Klekotka P . Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to severe plaque psoriasis. J Am Acad Dermatol. 2015;72(3):436-9. doi:10.1016/j.jaad.2014.10.026. PMID:25553889
   PubMed Web of Science ®Google Scholar
• Umezawa Y , Nakagawa H , Niiro H , Ootaki K , Japanese Brodalumab Study Group . Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2016;30(11):1957-60. doi:10.1111/jdv.13785. PMID:27358210
   PubMed Web of Science ®Google Scholar
• Papp K , Reich K , Leonardi C , et al. AMAGINE-1: A phase 3, randomized, doubleblind, placebo-controlled study of brodalumab in subjects with psoriasis. Br J Dermatol. 2014;171(6):e119-20
   Web of Science ®Google Scholar
• Papp K , Reich K , Leonardi C , et al. Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: Results of AMAGINE-1, a phase 3, randomized, double-blind, placebo-controlled study through week 12. J Am Acad Dermatol. 2015;72(5 Suppl 1):AB233
   Web of Science ®Google Scholar
• Papp KA , Reich K , Paul C , Blauvelt A , Baran W , Bolduc C , Toth D , Langley RG , Cather J , Gottlieb AB , et al. A prospective phase III, randomized, doubleblind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273-86. doi:10.1111/bjd.14493. PMID:26914406
   PubMed Web of Science ®Google Scholar
• Lebwohl M , Strober B , Menter A , Gordon K , Weglowska J , Puig L , Papp K , Spelman L , Toth D , Kerdel F , et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318-28. doi:10.1056/NEJMoa1503824. PMID:26422722
   PubMed Web of Science ®Google Scholar
• Farahnik B , Beroukhim K , Abrouk M , Nakamura M , Zhu TH , Singh R , Lee K , Bhutani T , Koo J . Brodalumab for the treatment of psoriasis: A review of phase III trials. Dermatol Ther. 2016;6(2):111-24. doi:10.1007/s13555-016-0121-x. PMID:27221323
   PubMed Web of Science ®Google Scholar
• Marcus KA . Overview of the July 19, 2016 DODAC meeting. Dermatologic and Ophthalmic Drugs Advisory Committee Meeting. 19 July 2015. https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/dermatologicandophthalmicdrugsadvisorycommittee/ucm511357.pdf (accessed 15 May 2017)
   Google Scholar
• Toichi E , Torres G , McCormick TS , Chang T , Mascelli MA , Kauffman CL , Aria N , Gottlieb AB , Everitt DE , Frederick B , et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol. 2006;177(7):4917-26. doi:10.4049/jimmunol.177.7.4917. PMID:16982934
   PubMed Web of Science ®Google Scholar
• Puig L . The role of IL 23 in the treatment of psoriasis. Expert Rev Clin Immunol. 2017;13(6):525-34. doi:10.1080/1744666X.2017.1292137. PMID:28165883
   PubMed Web of Science ®Google Scholar
• Teng MW , Bowman EP , McElwee JJ , Smyth MJ , Casanova JL , Cooper AM , Cua DJ . IL-12 and IL-23 cytokines: From discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719-29. doi:10.1038/nm.3895. PMID:26121196
   PubMed Web of Science ®Google Scholar
• Lowes MA , Suárez-Fariñas M , Krueger JG . Immunology of psoriasis. Annu Rev Immunol. 2014;32:227-55. doi:10.1146/annurev-immunol-032713-120225. PMID:24655295
   PubMed Web of Science ®Google Scholar
• Villanova F , Flutter B , Tosi I , Grys K , Sreeneebus H , Perera GK , Chapman A , Smith CH , Di Meglio P , Nestle FO . Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J Invest Dermatol. 2014;134:984-91. doi:10.1038/jid.2013.477. PMID:24352038
   PubMed Web of Science ®Google Scholar
• Keijsers RR , van der Velden HM , van Erp PE , de Boer-van Huizen RT , Joosten I , Koenen HJ , van de Kerkhof PC . Balance of Treg vs. T-helper cells in the transition from symptomless to lesional psoriatic skin. Br J Dermatol. 2013;168:1294-302. doi:10.1111/bjd.12236. PMID:23330679
   PubMed Web of Science ®Google Scholar
• Sofen H , Smith S , Matheson RT , Leonardi CL , Calderon C , Brodmerkel C , Li K , Campbell K , Marciniak SJ Jr , Wasfi Y , et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. Allergy Clin Immunol. 2014;133(4):1032-40. doi:10.1016/j.jaci.2014.01.025. PMID:24679469
   PubMedGoogle Scholar
• Gordon KB , Duffin KC , Bissonnette R , Prinz JC , Wasfi Y , Li S , Shen YK , Szapary P , Randazzo B , Reich K . A Phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2):136-44. doi:10.1056/NEJMoa1501646. PMID:26154787
   PubMed Web of Science ®Google Scholar
• Blauvelt A , Papp KA , Griffiths CE , Randazzo B , Wasfi Y , Shen YK , Li S , Kimball AB . Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405-17. doi:10.1016/j.jaad.2016.11.041. PMID:28057360
   PubMed Web of Science ®Google Scholar
• Reich K , Armstrong AW , Foley P , Song M , Wasfi Y , Randazzo B , Li S , Shen YK , Gordon KB . Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017 Mar; 76(3):418-31. doi:10.1016/j.jaad.2016.11.042. PMID:28057361
   PubMed Web of Science ®Google Scholar
• Kopp T , Riedl E , Bangert C , Bowman EP , Greisenegger E , Horowitz A , Kittler H , Blumenschein WM , McClanahan TK , Marbury T , et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature. 2015;521(7551):222-6. doi:10.1038/nature14175. PMID:25754330
   PubMed Web of Science ®Google Scholar
• Papp K , Thaçi D , Reich K , Riedl E , Langley RG , Krueger JG , Gottlieb AB , Nakagawa H , Bowman EP , Mehta A , et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173(4):930-9. doi:10.1111/bjd.13932. PMID:26042589
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov . A 64-week, phase 3, randomised, placebo-controlled, parallel design study to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (SCH 900222/MK-3222), followed by an optional long-term safety extension study, in subjects with moderate-to-severe chronic plaque psoriasis (protocol no. MK-3222 010). https://clinicaltrials.gov/ct2/show/NCT01722331
   Google Scholar
• ClinicalTrials.gov . A study to evaluate the efficacy and safety/tolerability of subcutaneous MK-3222 in participants with moderate-to-severe chronic plaque psoriasis (MK-3222-012). http://www.clinicaltrials.gov/ct2/show/NCT01936688
   Google Scholar
• ClinicalTrials.gov . A 52-week, phase 3, randomised, active comparator and placebo-controlled, parallel design study to evaluate the efficacy and safety/tolerability of subcutaneous SCH 9000222/MK3222, followed by an optional long-term safety extension study, in subjects with moderate to severe chronic plaque psoriasis. https://clinicaltrials.gov/ct2/show/NCT01729754
   Google Scholar
• Reich K , Papp K , Blauvelt A , et al. Tildrakizumab, a selective IL-23p19 antibody, in the treatment of chronic plaque psoriasis: Results from two randomized, controlled, phase 3 trials (reSURFACE 1 and reSURFACE 2). Poster presented at: the European Academy of Dermatology and Venereology Congress; October 1, 2016; Vienna, Austria.
   Google Scholar
• Galluzzo M , D'adamio S , Bianchi L , Talamonti M . Tildrakizumab for treating psoriasis. Expert Opin Biol Ther. 2017;17(5):645-57. doi:10.1080/14712598.2017.1304537. PMID:28271735
   PubMed Web of Science ®Google Scholar
• Krueger JG , Ferris LK , Menter A , Wagner F , White A , Visvanathan S , Lalovic B , Aslanyan S , Wang EE , Hall D , et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136(1):116-124.e7. doi:10.1016/j.jaci.2015.01.018. PMID:25769911
   PubMed Web of Science ®Google Scholar
• Papp KA , Blauvelt A , Bukhalo M , Gooderham M , Krueger JG , Lacour JP , Menter A , Philipp S , Sofen H , Tyring S , et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551-60. doi:10.1056/NEJMoa1607017. PMID:28423301
   PubMed Web of Science ®Google Scholar
• Papp KA , Tyring S , Lahfa M , Prinz J , Griffiths CE , Nakanishi AM , Zitnik R , van de Kerkhof PC , Melvin L , Etanercept Psoriasis Study Group, et al. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152(6):1304-12. doi:10.1111/j.1365-2133.2005.06688.x. PMID:15948997
   PubMed Web of Science ®Google Scholar
• Menter A , Tyring SK , Gordon K , Kimball AB , Leonardi CL , Langley RG , Strober BE , Kaul M , Gu Y , Okun M , et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106-15. doi:10.1016/j.jaad.2007.09.010. PMID:17936411
   PubMed Web of Science ®Google Scholar
• Reich K , Nestle FO , Papp K , Ortonne JP , Evans R , Guzzo C , Li S , Dooley LT , Griffiths CE , EXPRESS study investigators . Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367-74. doi:10.1016/S0140-6736(05)67566-6. PMID:16226614
   PubMed Web of Science ®Google Scholar
• Enbrel [prescribing information] . Thousand Oaks, (CA): Amgen; 1998
   Google Scholar
• Humira [prescribing information] . North Chicago (IL): Abbvie Inc; 2002
   Google Scholar
• Remicade [prescribing information] . Horsham (PA): Janssen Biotech Inc; 1998
   Google Scholar
• Kui R , Gál B , Gaál M , Kiss M , Kemény L , Gyulai R . Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis. J Dermatol. 2016;43(9):1018-23. doi:10.1111/1346-8138.13301. PMID:26892625
   PubMed Web of Science ®Google Scholar